Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cp-pca07

Phase 1

HHyundai Bioscience Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Castration-Resistant Prostate Cancer (CRPC)Not yet recruiting

Castration-Resistant Prostate Cancer (CRPC)Phase 1

Not yet recruiting

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Castration-Resistant Prostate Cancer (CRPC)

NCT07683013

Clinical

Trials by Indication[1]

Castration-Resistant Prostate Cancer (CRPC)1 trial

An Open-Label, Dose-Escalation, Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer

Not yet recruiting·HHyundai Bioscience Co., Ltd.·Phase 1·NCT07683013·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cp-pca07. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cp-pca07. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Hyundai Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHyundai Bioscience Co., Ltd.

Related News